We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




High Plasma Cortisol Levels Associated with Global Cognition Deterioration

By LabMedica International staff writers
Posted on 17 Aug 2016
Print article
Image: High plasma cortisol levels are associated with greater decline in global cognition, and accelerate the effect of beta-amyloid on decline in global cognition (Photo courtesy of Actinogen Medical).
Image: High plasma cortisol levels are associated with greater decline in global cognition, and accelerate the effect of beta-amyloid on decline in global cognition (Photo courtesy of Actinogen Medical).
Healthy older people with high plasma cortisol levels show a significantly greater risk of the presence of beta-amyloid in the brain, in addition to greater declines in global cognition over 54 months, compared with those with low cortisol levels.

The dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis is commonly measured according to plasma cortisol levels, and is linked to cognitive dysfunction, hippocampal atrophy and an increased risk for Alzheimer’s disease. However less is known of the role of cortisol levels in the prediction of cognitive decline or in moderating the effect of beta-amyloid in preclinical Alzheimer’s disease.

Scientists at the Florey Institute of Neuroscience and Mental Health (Melbourne, Australia) evaluated 401 cognitively normal adults enrolled in the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL) who had undergone beta-amyloid neuroimaging at a single time point. The subjects also had comprehensive assessment of neuropsychological measures including global cognition, episodic memory and executive function at baseline, as well as follow-ups at 18, 36, and 54 months.

The team found that after 54 months higher plasma cortisol levels at baseline were associated with a 2.2 times greater risk of having beta-amyloid presence. The higher cortisol levels were also associated with increased declines in global cognition in general, and, compared with older adults with low cortisol and beta-amyloid deposits, those with high cortisol and beta-amyloid showed faster declines in various measures, with Cohen’s d values of 0.69 for episodic memory, 0.42 for global cognition, and 0.31 for attention. The effects were observed after adjusting for factors age, education, premorbid intelligence, Apolipoprotein E (APOE) and Brain-derived neurotrophic factor (BDNF) genotypes, subjective memory complaints, vascular risk factors, and depression and anxiety symptoms.

The authors concluded that in cognitively normal older adults, high plasma cortisol levels are associated with greater decline in global cognition, and accelerate the effect of beta-amyloid on decline in global cognition, episodic memory, and attention over at 54-month period. These results suggest that therapies targeted toward lowering plasma cortisol and beta-amyloid levels may help mitigate cognitive decline in the preclinical phase of Alzheimer’s disease. The study was presented at the Alzheimer’s Association International Conference, held July 22-28, 2016, in Toronto, ON, Canada.

Related Links:
Florey Institute of Neuroscience and Mental Health


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2
New
Anti-HHV-6 IgM Assay
anti-HHV-6 IgM ELISA (semiquant.)

Print article

Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.